Bristol-Myers Squibb stock holds firm after a $2.04 EPS beat
Published on 08/18/2026 at 21:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock held near $64.72 on August 17, 2026, after the company said on July 30, 2026 that quarterly EPS reached $2.04 and revenue came in at $12.97 billion.
The quarter also beat consensus by $0.44 per share on EPS and by $1.23 billion on sales, while full-year 2026 EPS guidance stayed at $6.75 to $7.00.
Quarterly beat still matters
The latest quarter gives investors a clean comparison point: EPS of $2.04 versus $1.60 expected, with revenue up 5.7% year over year to $12.97 billion. That spread is large enough to keep earnings quality, not just valuation, at the center of the debate.
Market data showed the shares at $64.71 to $64.72 on August 17, 2026, with a market value of $132.18 billion and a 52-week range of $42.52 to $68.10. The stock was also trading within a few dollars of its 12-month high, which leaves less room for disappointment than earlier in the summer.
Guidance sets the range
Management's fiscal 2026 EPS guide of $6.75 to $7.00 implies that the second-quarter result was not a one-off event. Analysts were centered close to $6.95 for the year, keeping the company's own outlook and the Street's view tightly aligned.
The consensus price target stood at $66.06, a narrow gap from the latest close and a sign that current coverage sees a measured valuation case rather than a dramatic rerating.
Opdivo and Eliquis remain core
In the product mix, Eliquis and Opdivo remain the reference products for Bristol-Myers Squibb's revenue base, and the second-quarter report still points to a business built on large, cash-generating franchises. For investors, that combination of scale, guidance and a still-solid share price is the main setup.
Shares closed at $64.72 on August 17, 2026, and the stock's 52-week high of $68.10 is now the key nearby marker.
More on Bristol-Myers Squibb stock
Company: Bristol-Myers Squibb Company
ISIN: US1078421011
Ticker: BMY
Exchange: NYSE
Price (as of August 17, 2026, 4:00 p.m. ET): $64.72 USD
Market cap: $132.18 billion (as of August 18, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
Next earnings date: November 3, 2026
